AMARYL
What it isSulfonylurea that closes beta-cell KATP channels to release insulin; type 2 diabetes.
Why this oneIt is inexpensive and once daily, with less persistent hypoglycemia than glyburide but more than many newer agents.
What limits itHypoglycemia can be prolonged in renal impairment; weight gain and progressive loss of efficacy also limit use.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Type 2 diabetes mellitus (adjunct to diet/exercise) | Adults | 1–2 mg QD | titrate to glycemic response | 8 mg QD |
| Type 2 diabetes mellitus | Elderly or renal impairment | 1 mg QD | 8 mg QD |
Titration Increase in 1–2 mg increments no more frequently than every 1–2 weeks
Renal Start 1 mg QD and titrate slowly (increased hypoglycemia risk)
Hepatic Undefined (increased susceptibility to hypoglycemia; no specific dose adjustment stated)
Pregnancy No clear teratogenic risk in humans; discontinue at least 2 weeks before expected delivery (sulfonylureas cross placenta → neonatal hypoglycemia).
Lactation Undefined
NO BOXED WARNINGS
Principal riskHypoglycemia, prolonged in renal impairment
Cost, est. cash$5–$150/month
Generic entry2005
Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent
Defining liabilitySevere and sometimes prolonged hypoglycemia, particularly with renal impairment or missed meals.

Open Glimepiride in the interactive console ↗

